Blood Sugar and Blood Lipid Supplement Clinical Trial Services

A blood sugar and blood lipid supplement clinical trial (metabolic health supplement clinical trial) is a study in volunteers who receive the actual product. It measures biochemical values from blood samples at set time points, such as fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipids and the homeostasis model assessment of insulin resistance (HOMA-IR), and compares them with a control group. The results are verifiable quantitative data on whether the formula changes these markers under controlled study conditions.

The market for metabolic health supplements, which relate to blood sugar, blood lipids and the body’s sensitivity to insulin, continues to grow in Thailand and worldwide. Brand owners who want to communicate a product’s effect on these values must have scientific evidence for their statements and must choose wording within the limits of food law, because dietary supplements cannot make claims to treat, cure or prevent disease, including diabetes. This service therefore designs studies to measure biochemical markers in volunteers, not to prove a treatment effect on disease.

The main outcomes of these studies are values measured from blood samples in the laboratory (laboratory biomarkers), so the data are quantitative and traceable. VISBIO Co., Ltd. provides study design, project management and project coordination for clinical studies of metabolic health supplements, working with a network of partner clinical research sites and hospitals. This includes an additional blood biochemistry service (biomarker add-on), in which the partner research site collects blood samples and sends them for laboratory analysis using the same method throughout the study. The service runs from planning the study protocol to the final report, under Good Clinical Practice (GCP), for sponsors in Thailand and abroad.

Under the Food Act B.E. 2522 (1979), the approval of dietary supplements by the Thai Food and Drug Administration (Thai FDA) focuses mainly on product safety and quality and does not confirm clinical efficacy. The food serial number (Thai FDA number) on the label is therefore not evidence that a product changes consumers’ blood sugar or blood lipid levels.

Data from in vitro or animal studies have scientific value and help explain the mechanism of action, but they do not measure effects in humans directly. Metabolic health clinical studies therefore build empirical evidence from the volunteers’ own laboratory values. The resulting data support product development and evidence-based communication.

This gap matters to brand owners because the market is full of blood sugar and blood lipid claims, consumers increasingly ask whether products “really work”, and some modern trade buyers and export partners have started to request supporting scientific documents before they list a product.

Matthews et al. (1985) developed the homeostasis model assessment (HOMA), which estimates insulin resistance and pancreatic beta-cell function from fasting plasma glucose and insulin concentrations. Insulin resistance estimated with this model correlates with results from more complex reference methods such as the euglycemic clamp. The HOMA-IR index is therefore widely used in clinical research to track changes in insulin sensitivity, because it can be calculated from values that are easy to measure in clinical settings. The original paper notes, however, that model estimates have limited precision, so the sample size and measurement time points must take this into account.

Yin et al. (2008) was a 3-month pilot study in patients with type 2 diabetes, part of which randomly compared berberine, a plant alkaloid, with the drug metformin. HbA1c, fasting blood glucose and triglycerides decreased significantly in the berberine group. This study assessed berberine in the context of treating patients with diabetes, so its results cannot be used for claims about dietary supplements, but it is a clear example of the systematic use of blood biochemistry as a primary endpoint.

Anderson et al. (2004) isolated type-A polyphenol polymers from cinnamon that increased insulin-dependent glucose metabolism in in vitro tests and had antioxidant activity. Mechanistic data of this kind can justify the choice of clinical study endpoints, such as fasting blood glucose and indices that reflect insulin sensitivity, but effects in humans still need to be confirmed in clinical studies.

A key challenge in designing these studies is choosing biochemical markers that match the message to be communicated, and standardizing blood collection at every time point, for example the fasting period before blood is drawn, which the partner research site carries out according to the protocol.

Every study follows GCP and takes into account the particular nature of metabolic outcomes, which rely on blood sampling and laboratory analysis using the same method throughout the study. VISBIO designs the study and manages it from planning through to delivery of the report, while volunteer recruitment, blood collection and volunteer care are handled by the physicians and investigators of the research site responsible for the study.

Step 1: Consultation and protocol design

VISBIO analyzes the product’s characteristics, the effects the company wants to claim and the product’s objectives together with the investigators of the partner research site to define a suitable study plan, including the choice of a primary biomarker endpoint consistent with the mechanism of action of the key ingredients. This step covers volunteer inclusion/exclusion criteria that suit the claim and a sample size estimation that gives adequate statistical power.

Step 2: Approval from a human research ethics committee

Before any data are collected, the protocol and the informed consent documents must be approved by a human research ethics committee (Institutional Review Board, IRB) in every case. VISBIO coordinates the preparation of documents with the site’s investigators and follows up on the revisions requested by the committee until approval is granted.

Step 3: Volunteer recruitment and screening

Once approval is granted, the research site responsible for the study recruits and screens volunteers according to the protocol. The site’s physicians and investigators make sure that every volunteer receives complete information, gives written informed consent and has screening blood tests before joining, to confirm that their baseline values are within the range set by the protocol. VISBIO coordinates schedules and project readiness between the sponsor and the research site.

Step 4: Study conduct and data collection

Volunteers receive the product, and data are collected at the time points set in the protocol. The research site collects blood samples to measure values relevant to the claim, such as fasting blood glucose (FBG), HbA1c, blood lipids (a lipid profile of total cholesterol, triglycerides, HDL and LDL) and the HOMA-IR index (Matthews et al., 1985), together with anthropometric measurements such as body mass index (BMI) and waist circumference, and adverse event recording throughout the study. The site’s investigators assess and safeguard volunteer safety, while VISBIO, as project manager, monitors progress and data completeness.

Step 5: Data analysis and reporting

All biochemical data are analyzed statistically according to a pre-specified statistical analysis plan (SAP) and summarized in a full scientific report in an internationally used format. VISBIO coordinates the analysis and delivers the report to the sponsor. The report supports product development and evidence-based communication.

This service is designed for dietary supplements that aim to communicate effects on blood sugar or blood lipids. Examples of suitable ingredient types include:

Some markets permit ingredients such as berberine in dietary supplements under local regulations; study designs follow the rules of the target market.

Clinical study data on metabolic health are a tangible strategic asset, because they rely on values actually measured in the laboratory that can be traced back.

Verifiable biochemical data

Laboratory values, such as changes in FBG, HbA1c or HOMA-IR compared with a control group, are objective, traceable data that support formula development and evidence-based communication. Any use of the data on labels or in advertising must comply with food law and obtain approval where the law requires it.

Premium product positioning

Products backed by biochemical data from clinical studies can be positioned in the premium segment on a reasoned and credible basis. In a market full of blood sugar and blood lipid claims, actually measured data create differentiation with real scientific weight.

Negotiating with modern trade and export partners

Many modern trade buyers and export partners in the health category request supporting scientific documents for their assessment. A clinical study report with biochemical data makes negotiations and listing in these channels smoother.

Reducing legal risk and expanding into export markets

Metabolic health claims backed by clinical study evidence reduce the risk that advertising will be considered exaggerated under the Food Act B.E. 2522 (1979), but they do not replace the advertising approval process. For export markets with strict regulations, a report designed and prepared in line with international practice is part of the documentation used to prepare for market entry, although each country has its own requirements.

1. Dietary supplements sold in Thailand must be approved by the Thai FDA and hold a food serial number (Thai FDA number) before the study starts. For products from international sponsors, VISBIO assesses the legal requirements with the research site on a project-by-project basis.
2. VISBIO and the research site design the study plan specifically for each product and its claims.
3. Every study must be approved by a human research ethics committee before it starts, without exception.

For brands that want to build evidence at every level, VISBIO supports laboratory testing such as alpha-glucosidase inhibition, alpha-amylase inhibition and LDL cholesterol production testing in cells, which are brought together in the laboratory testing service for blood sugar balance products, through to clinical studies in volunteers. Laboratory results that show the mechanism of action help select clinical study endpoints consistently. GCP applies to studies in humans, while laboratory work follows the test method of each assay. Planning every level of evidence with a single coordinator keeps the data at each stage consistent and free of gaps.

Which values does this study measure?

The main endpoints are biochemical values from blood samples, such as fasting blood glucose (FBG), HbA1c, blood lipids and the HOMA-IR index, together with anthropometric measurements such as body mass index and waist circumference, and adverse event recording throughout the study. The values chosen depend on the message the product wants to communicate.

What is HOMA-IR?

HOMA-IR is an index calculated from fasting blood glucose and insulin levels to estimate insulin resistance. The model was developed by Matthews et al. (1985) and is widely used in clinical research because it can be calculated from values that are easy to measure.

Can study results be used to say that a product treats or prevents diabetes?

No. Dietary supplements cannot make claims to treat, cure or prevent disease. This study measures changes in biochemical markers in volunteers to support product development and evidence-based communication, and the wording on labels and in advertising must comply with food law.

Can laboratory test results replace studies in volunteers?

No. In vitro or animal data help explain mechanisms and select endpoints, but they do not measure effects in humans directly, so they must be confirmed by studies in volunteers.

Who draws blood and looks after the volunteers?

The physicians and investigators of the partner research site responsible for the study screen the volunteers, collect blood samples and look after the volunteers. VISBIO designs, manages and coordinates the study between the sponsor and the research site, from planning through to delivery of the report.

Do study results guarantee advertising approval?

No. Study results support product development and evidence-based communication. Use on labels or in advertising must comply with the law and obtain approval from the relevant authorities where the law requires it. VISBIO does not guarantee study outcomes or regulatory decisions.

If you are interested in a clinical trial for your metabolic health supplement, contact VISBIO for a free initial consultation through the following channels:

• Contact form: https://visbio.co.th/en/contact-us/
• LINE Official Account: @visbio
• Email: service@visbio.co.th
• Phone: 098-635-4197 (+66 98 635 4197)
• Timeline: please ask our team directly.

See all clinical trial services on VISBIO’s clinical trial page.

• VISBIO’s role: VISBIO designs studies and provides project management and project coordination with a network of partner clinical research sites and hospitals, for sponsors in Thailand and abroad. Volunteers are recruited and cared for by the physicians and investigators of the site responsible for the study.
• Research ethics: Every study in humans starts only after approval by a human research ethics committee and is conducted in line with Good Clinical Practice (GCP). All volunteers give informed consent after receiving complete information.
• Drugs and herbal medicines: Studies must follow the requirements of the Thai Food and Drug Administration (Thai FDA) that apply to the product. The sponsor, the research site and VISBIO plan these steps together from the start of the project.
• Use of results: Study results support product development and evidence-based communication. Use on labels or in advertising must comply with the law for each product type, with approval from the relevant authorities where the law requires it. VISBIO does not guarantee study outcomes or regulatory decisions.
• Foods and dietary supplements: Study results are not a claim that a product diagnoses, treats, cures, mitigates or prevents any disease.
• Timeline: This depends on the study design and the approval process. Please ask our team directly.

References:

1. Anderson, R. A., Broadhurst, C. L., Polansky, M. M., Schmidt, W. F., Khan, A., Flanagan, V. P., Schoene, N. W., & Graves, D. J. (2004). Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. Journal of Agricultural and Food Chemistry, 52(1), 65–70. https://doi.org/10.1021/jf034916b
2. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883
3. Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712–717. https://doi.org/10.1016/j.metabol.2008.01.013